K. M. Rowland
About
K. M. Rowland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, K. M. Rowland has authored 26 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in K. M. Rowland's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). K. M. Rowland is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). K. M. Rowland collaborates with scholars based in United States. K. M. Rowland's co-authors include Charles L. Loprinzi, Angela W. Miser, J A Mailliard, Jeff A. Sloan, Neil M. Ellison, Ann Marie Dose, Judith R. OʼFallon, M H Veeder, Richard M. Goldberg and Nora Burnham and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and American Journal of Clinical Oncology.
In The Last Decade
K. M. Rowland
24 papers receiving 706 citations
Peers
K. M. Rowland
Robert A. Nelimark United States
Phillip J. Stella United States
Hasnain Khandwala Canada
Meenali Chitnis United Kingdom
Amanda M. Shearman United States
Ichiro Horie Japan
Mustafa Akkіprіk Türkiye
Chika Tazawa Japan
Shelby A. Terstriep United States
Hany Soliman France
Citations per year, relative to K. M. Rowland K. M. Rowland (= 1×)
peers
Robert A. Nelimark
Countries citing papers authored by K. M. Rowland
Since
Specialization
Citations
This map shows the geographic impact of K. M. Rowland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. M. Rowland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. M. Rowland more than expected).
Fields of papers citing papers by K. M. Rowland
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by K. M. Rowland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. M. Rowland. The network helps show where K. M. Rowland may publish in the future.
Co-authorship network of co-authors of K. M. Rowland
This figure shows the co-authorship network connecting the top 25 collaborators of K. M. Rowland. A scholar is included among the top collaborators of K. M. Rowland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. M. Rowland. K. M. Rowland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Flora, Daniel, et al.. (2019). Abstract GS6-02: A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603. Cancer Research. 79(4_Supplement). GS6–2.
2.
Molina, Julian R., Grace K. Dy, Nathan R. Foster, et al.. (2011). A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study.. Journal of Clinical Oncology. 29(15_suppl). 7513–7513.
3.
Atherton, Philip J., Daniel Szydlo, Debra L. Barton, et al.. (2010). Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB.. Journal of Clinical Oncology. 28(15_suppl). 9139–9139.
4.
Loprinzi, Charles L., Rui Qin, Philip J. Stella, et al.. (2009). Pregabalin for hot flashes in women: NCCTG trial N07C1. Journal of Clinical Oncology. 27(15_suppl). 9513–9513.
5.
Rowland, K. M., et al.. (2009). Meta-analysis of adverse event rates in 15 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials for the development of adverse event stopping rules.. Cancer Research. 69(2_Supplement). 6149–6149.
6.
Nguyen, Freddy T., et al.. (2009). Optical coherence tomography (OCT) as a diagnostic tool for the real-time intraoperative assessment of breast cancer surgical margins.. Cancer Research. 69(2_Supplement). 802–802.
7.
Schild, Steven E., Yingwei Qi, Alex A. Adjei, et al.. (2008). Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Journal of Clinical Oncology. 26(15_suppl). 8076–8076.
8.
Rizvi, Naiyer A., Mark G. Kris, V. A. Miller, et al.. (2008). Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Journal of Clinical Oncology. 26(15_suppl). 8053–8053.
9.
Ansari, Rafat, Mark A. Socinski, J. K. Choksi, et al.. (2008). A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded). Journal of Clinical Oncology. 26(15_suppl). 19077–19077.
10.
Grothey, Axel, Lowell L. Hart, K. M. Rowland, et al.. (2008). Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. Journal of Clinical Oncology. 26(15_suppl). 4010–4010.
11.
Marsh, Robert, Caio M. Rocha Lima, David T. Levy, et al.. (2007). A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. 30(1). 26–31.
12.
Loprinzi, Charles L., Amylou C. Dueck, Debra L. Barton, et al.. (2007). Gabapentin for hot flashes in men: NCCTG trial N00CB. Journal of Clinical Oncology. 25(18_suppl). 9005–9005.
13.
Steen, Preston D., K. M. Rowland, J. W. Kugler, et al.. (2004). A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. Journal of Clinical Oncology. 22(14_suppl). 639–639.
14.
Steen, Preston D., K. M. Rowland, J. W. Kugler, et al.. (2004). A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. Journal of Clinical Oncology. 22(14_suppl). 639–639.
15.
Adjei, Alex A., S. Nair, Nicholas F. Reuter, et al.. (2004). Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. Journal of Clinical Oncology. 22(14_suppl). 7070–7070.
16.
Adjei, Alex A., Nicholas F. Reuter, Sumithra J. Mandrekar, et al.. (2004). Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. Journal of Clinical Oncology. 22(14_suppl). 7070–7070.
17.
Galanis, Evanthia, Jan C. Buckner, Patrick A. Burch, et al.. (1998). Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.. Journal of Clinical Oncology. 16(9). 2953–2958.
18.
Loprinzi, Charles L., Jeff A. Sloan, Alexandra Hammer, et al.. (1997). Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer.. Journal of Clinical Oncology. 15(3). 969–973.
19.
Ellison, Neil M., Charles L. Loprinzi, J Kugler, et al.. (1997). Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients.. Journal of Clinical Oncology. 15(8). 2974–2980.
20.
Goldberg, Richard M., Charles L. Loprinzi, Judith R. OʼFallon, et al.. (1994). Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.. Journal of Clinical Oncology. 12(1). 155–158.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert A. Nelimark Breakdown of academic impact, for papers by Phillip J. Stella Breakdown of academic impact, for papers by Hasnain Khandwala Breakdown of academic impact, for papers by Meenali Chitnis Breakdown of academic impact, for papers by Amanda M. Shearman Breakdown of academic impact, for papers by Ichiro Horie Breakdown of academic impact, for papers by Mustafa Akkіprіk Breakdown of academic impact, for papers by Chika Tazawa Breakdown of academic impact, for papers by Shelby A. Terstriep Breakdown of academic impact, for papers by Hany Soliman